Death MI or revascularization 45 vs 29 p 006 respectively Stent thrombosis 12 vs 05 p 011 respectively Trial design NSTEMI patients initially treated with fondaparinux 25 mg SQ were randomized to ID: 933712
Download Presentation The PPT/PDF document "FUTURA/OASIS-8 Major bleeds/minor bleeds..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
FUTURA/OASIS-8
Major bleeds/minor bleeds/vascular access site complications at 48 hours: 4.7% of the low-dose heparin group vs. 5.8% of the standard-dose heparin group (p = 0.27)
Death, MI, or revascularization: 4.5% vs. 2.9% (p = 0.06), respectivelyStent thrombosis: 1.2% vs. 0.5% (p = 0.11), respectively
Trial design: NSTEMI patients initially treated with fondaparinux 2.5 mg SQ were randomized to unfractionated heparin 50 U/kg regardless of glycoprotein IIb/IIIa inhibitor use (n = 1,024) vs. unfractionated heparin 60 U/kg with glycoprotein IIb/IIIa inhibitor or 85 U/kg without glycoprotein IIb/IIIa inhibitor (n = 1,002).
Results
Conclusions
Among ACS patients initially treated with fondaparinux, PCI can be safely performed with the addition of unfractionated heparinLow-dose and standard-dose heparin had the same frequency of bleeding eventsLow-dose heparin therapy was associated with a marginally significant increase in ischemic events
FUTURA/OASIS-8 Trial Group. JAMA 2010;Aug 31:[Epub]
(p
= 0.27)
Low-dose heparin
Standard-dose heparin
%
Major/minor bleed, or vascular complication
4.7
4.5
5.8
2.9
(p
= 0.06)
Death, MI, or revascularization